Gilead Sciences, Inc.
GILD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882095
In the last 90 days, Gilead Sciences, Inc. insiders filed 0 open-market purchases and 11 sales; 2,292 institutions reported holding it in 13F filings for Q2 2026, worth $140.9B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $15.4M in total
- 11
- 13F holdersQ2 2026, −8 vs. previous quarter
- 2,292
- 13F valueReported value at the end of Q2 2026
- $140.9B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GILD, Q2 2026
No superinvestor reported holding GILD at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Gilead Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)4:30 PM ET | Sep 15 | 1 day | Dickinson Andrew DChief Financial Officer | SSale | −3.00K | $145.29 | −$435.9K | −1.8%164.1K after | 10b5-1 |
| Sep 16, 2026 (view filing)4:27 PM ET | Sep 15 | 1 day | Mercier JohannaChief Comm & Corp Aff Officer | SSale | −3.00K | $144.22 | −$432.6K | −2.5%116.7K after | 3 lots10b5-1 |
| Sep 2, 2026 (view filing)4:12 PM ET | Sep 1 | 1 day | O'Day Daniel PatrickChairman & CEO | SSale | −15.0K | $148.64 | −$2.23M | −2.5%577.1K after | 3 lots10b5-1 |
| Aug 27, 2026 (view filing)6:44 PM ET | Aug 26 | 1 day | Welters AnthonyDirector | SSale | −18.0K | $148.62 | −$2.68M | −58.3%12.9K after | 4 lots10b5-1 |
| Aug 21, 2026 (view filing)7:22 PM ET | Aug 20 | 1 day | Bluestone JeffreyDirector | SSale | −5.00K | $145.02 | −$725.1K | −33.2%10.1K after | 5 lots10b5-1 |
| Aug 18, 2026 (view filing)7:06 PM ET | Aug 17 | 1 day | Dickinson Andrew DChief Financial Officer | SSale | −3.00K | $138.36 | −$415.1K | −1.8%165.6K after | 10b5-1 |
| Aug 18, 2026 (view filing)6:54 PM ET | Aug 17 | 1 day | Mercier JohannaChief Comm & Corp Aff Officer | SSale | −28.0K | $137.64 | −$3.85M | −19.1%118.2K after | 2 lots10b5-1 |
| Aug 4, 2026 (view filing)5:40 PM ET | Aug 3 | 1 day | O'Day Daniel PatrickChairman & CEO | SSale | −15.0K | $130.31 | −$1.95M | −2.5%592.1K after | 3 lots10b5-1 |
| Jul 16, 2026 (view filing)6:08 PM ET | Jul 15 | 1 day | Dickinson Andrew DChief Financial Officer | SSale | −3.00K | $129.93 | −$389.8K | −1.7%168.6K after | 10b5-1 |
| Jul 16, 2026 (view filing)4:54 PM ET | Jul 15 | 1 day | Mercier JohannaChief Comm & Corp Aff Officer | SSale | −3.00K | $129.92 | −$389.8K | −2.4%121.2K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Gilead Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 121,844,108 | $15.4B | 0.23% | +2,833,135+2.4% | Added |
| Vanguard Capital Management LLC | 81,091,734 | $10.2B | 0.22% | +436,958+0.5% | Added |
| FMR LLC | 66,870,816 | $8.45B | 0.37% | −5,035,474−7.0% | Reduced |
| State Street Corp | 61,216,552 | $7.73B | 0.23% | +1,357,967+2.3% | Added |
| Capital World Investors | 40,988,975 | $5.18B | 0.61% | −294,958−0.7% | Reduced |
| Invesco Ltd. | 39,819,151 | $5.03B | 0.40% | −1,761,672−4.2% | Reduced |
| Vanguard Portfolio Management LLC | 35,316,168 | $4.46B | 0.20% | +186,703+0.5% | Added |
| Geode Capital Management, LLC | 30,065,642 | $3.80B | 0.20% | +339,590+1.1% | Added |
| Price T Rowe Associates Inc | 29,996,694 | $3.79B | 0.38% | +3,748,586+14.3% | Added |
| Morgan Stanley | 24,004,354 | $3.03B | 0.16% | +705,059+3.0% | Added |